Janux Therapeutics Inc (JANX)

Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	49.13% 1.252	2.461	2.517	1.057	2.048
Operating Expenses	15.14% 21.41	18.60	18.33	21.80	22.33
Benefits Costs and Expenses	12.61% 16.01	14.22	14.09	18.57	19.51
Costs And Expenses	12.61% 16.01	14.22	14.09	18.57	19.51
Operating Income/Loss	24.94% -20.16	-16.14	-15.81	-20.75	-20.28
Nonoperating Income/Loss	23.34% 5.401	4.379	4.245	3.24	2.822
Income/Loss From Continuing Operations Before Tax	25.53% -14.76	-11.76	-11.57	-17.51	-17.46
Income/Loss From Continuing Operations After Tax	25.53% -14.76	-11.76	-11.57	-17.51	-17.46
Net Income/Loss	25.53% -14.76	-11.76	-11.57	-17.51	-17.46
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	5,357% 49.05	0.8989	45.71	41.84	41.76
Diluted Average Shares	5,357% 49.05	0.8989	45.71	41.84	41.76
Basic Earnings Per Share	25.00% -0.30	-0.24	-0.25	-0.42	-0.42
Diluted Earnings Per Share	25.00% -0.30	-0.24	-0.25	-0.42	-0.42
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-